KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2025)

Vir Biotechnology's Accumulated Expenses history spans 8 years, with the latest figure at $83.0 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 15.74% to $83.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.0 million, a 15.74% decrease, with the full-year FY2025 number at $83.0 million, down 15.74% from a year prior.
  • Accumulated Expenses hit $83.0 million in Q4 2025 for Vir Biotechnology, up from $68.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for VIR hit a ceiling of $489.1 million in Q4 2022 and a floor of $3.1 million in Q1 2023.
  • Historically, Accumulated Expenses has averaged $119.7 million across 5 years, with a median of $82.8 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: crashed 89.01% in 2022 and later soared 2225.72% in 2024.
  • Tracing VIR's Accumulated Expenses over 5 years: stood at $236.5 million in 2021, then skyrocketed by 106.79% to $489.1 million in 2022, then crashed by 78.69% to $104.2 million in 2023, then dropped by 5.47% to $98.5 million in 2024, then dropped by 15.74% to $83.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for VIR at $83.0 million in Q4 2025, $68.4 million in Q3 2025, and $82.7 million in Q2 2025.